Does Blue Cross Blue Shield of Massachusetts Cover Jardiance?

BCBSMA Formulary Placement for Jardiance

Blue Cross Blue Shield of Massachusetts lists Jardiance on its commercial formulary as a preferred-brand or non-preferred-brand medication, depending on the specific plan. Most HMO Blue, PPO Blue, and employer-sponsored plans through BCBSMA include empagliflozin with some form of utilization management.

BCBSMA uses a multi-tier formulary structure. Tier 1 covers generics. Tier 2 covers preferred brands. Tier 3 and Tier 4 cover non-preferred brands and specialty drugs, respectively. Jardiance lands on Tier 3 in most BCBSMA commercial plan designs, though some employer-customized formularies place it on Tier 2 when the plan sponsor negotiates preferred SGLT2 inhibitor access. The distinction matters: Tier 2 copays typically run $25 to $45 per fill, while Tier 3 copays range from $50 to $90.

The American Diabetes Association's Standards of Care 2024 recommends SGLT2 inhibitors as second-line therapy for patients with type 2 diabetes who have established cardiovascular disease, heart failure, or chronic kidney disease. This guideline positioning strengthens the clinical argument for coverage when filing appeals. BCBSMA's pharmacy and therapeutics committee reviews these guideline updates annually when setting formulary placement [1].

Patients enrolled in BCBSMA Medicare Advantage plans (Blue Medicare Rx) may see different tier placement. Medicare Part D formularies are governed by CMS requirements, and Jardiance typically falls on the Part D preferred-brand tier with a 25% coinsurance during the initial coverage phase. After reaching the coverage gap threshold ($5 to 880 in total drug costs for 2025), Medicare enrollees receive manufacturer discounts under the Inflation Reduction Act provisions that cap annual out-of-pocket drug spending at $2,000 [2].

Prior Authorization Requirements

BCBSMA requires prior authorization for Jardiance on the majority of its plans, and prescribers should expect to document specific clinical criteria before the insurer approves coverage.

The standard PA criteria for empagliflozin on BCBSMA commercial plans include: a confirmed diagnosis of type 2 diabetes mellitus with HbA1c documented within the past 90 days, evidence that the patient has tried or cannot tolerate metformin (unless contraindicated), and confirmation that the prescriber has considered formulary-preferred alternatives. Some BCBSMA plans also require documentation that the patient's estimated glomerular filtration rate (eGFR) is above 20 mL/min/1.73 m², consistent with the FDA-revised prescribing information for empagliflozin [3].

Step therapy is the most common barrier. BCBSMA typically mandates a trial of metformin (or documented intolerance/contraindication) before approving an SGLT2 inhibitor. For patients with established atherosclerotic cardiovascular disease (ASCVD) or heart failure, prescribers can often bypass step therapy by citing the 2023 ADA/EASD consensus report recommending SGLT2 inhibitors independent of HbA1c level in these populations [4].

PA turnaround at BCBSMA is typically 48 to 72 hours for standard requests. Urgent requests receive a decision within 24 hours. Denials can be appealed through a two-level internal review process, followed by an external review through the Massachusetts Office of Patient Protection if needed.

What Jardiance Costs on BCBSMA Plans

The out-of-pocket price for Jardiance varies widely across BCBSMA plan designs, but most commercially insured members pay between $25 and $90 per 30-day supply after prior authorization approval.

Without insurance, Jardiance carries a wholesale acquisition cost of approximately $590 per month for the 25 mg dose. That sticker price rarely reflects what an insured BCBSMA member actually pays. A Tier 3 placement on a typical BCBSMA employer plan means a fixed copay (commonly $50 to $75) or coinsurance of 25% to 35% after any applicable deductible. High-deductible health plans paired with HSAs may require the member to pay the full negotiated rate until meeting their deductible.

Boehringer Ingelheim offers a manufacturer savings card that can reduce commercial copays to as little as $10 per month for eligible patients. This card cannot be used with Medicare, Medicaid, or other federal insurance programs. BCBSMA members with commercial coverage can stack the savings card with their plan benefit, applying the manufacturer discount after the plan pays its share.

For BCBSMA Medicare Advantage enrollees, the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective 2025) provides a meaningful ceiling. Patients taking Jardiance who also use insulin or other brand-name medications will hit that cap and pay nothing further for the remainder of the calendar year. The CMS Part D redesign applies across all Part D plans, including BCBSMA's Blue Medicare Rx offerings [5].

Massachusetts state law also requires insurers to cover FDA-approved diabetes medications without imposing quantity limits that conflict with the prescribing information. Chapter 176O, Section 16 of Massachusetts General Laws mandates that health plans provide coverage for "medically necessary" diabetes treatments, which strengthens a patient's position when appealing a Jardiance denial [6].

Clinical Evidence Supporting Coverage

Jardiance has one of the strongest cardiovascular evidence bases of any oral diabetes medication, which is a factor BCBSMA's pharmacy committee weighs when maintaining formulary coverage.

The EMPA-REG OUTCOME trial (N=7,020), published in the New England Journal of Medicine in 2015, demonstrated that empagliflozin 10 mg or 25 mg reduced the risk of cardiovascular death by 38% compared with placebo in patients with type 2 diabetes and established cardiovascular disease (HR 0.62 to 95% CI 0.49 to 0.77, P<0.001) [7]. All-cause mortality fell by 32%. This trial was the first to show a mortality benefit for any diabetes drug in this population, and it reshaped how insurers evaluate SGLT2 inhibitor coverage.

The EMPEROR-Reduced trial (N=3,730) extended empagliflozin's evidence into heart failure with reduced ejection fraction, regardless of diabetes status. Patients on empagliflozin experienced a 25% reduction in the composite of cardiovascular death or heart failure hospitalization compared with placebo [8]. The FDA subsequently approved Jardiance for heart failure with reduced ejection fraction in 2021, and for heart failure across the full ejection fraction spectrum in 2022 after the EMPEROR-Preserved trial showed benefit in HFpEF as well.

For chronic kidney disease, the EMPA-KIDNEY trial (N=6,609) published in the New England Journal of Medicine in 2023 showed that empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) in patients with CKD, with or without diabetes [9]. This led to the FDA expanding Jardiance's indication to include chronic kidney disease at risk of progression.

Dr. Silvio Inzucchi, professor of medicine at Yale School of Medicine, stated regarding the EMPA-REG results: "These findings represent a genuine advance in our ability to reduce the toll of cardiovascular disease in patients with diabetes. The magnitude of the mortality benefit was unexpected and has changed clinical practice."

The accumulated trial evidence means that when a BCBSMA prior authorization requires clinical justification, prescribers have multiple large, high-quality randomized controlled trials to reference.

How to Get Jardiance Approved Through BCBSMA

Getting Jardiance covered requires coordination between the patient, prescriber, and BCBSMA's pharmacy benefit team. The process follows a predictable sequence.

First, the prescriber submits a prior authorization request to BCBSMA. This can be done electronically through the BCBSMA provider portal or via fax. The request should include the patient's diagnosis (ICD-10 code E11.x for type 2 diabetes, or I50.x for heart failure), recent HbA1c and eGFR values, a list of previously tried diabetes medications with dates and outcomes, and the clinical rationale for choosing empagliflozin over formulary alternatives.

Second, if the PA is denied, the prescriber can request a peer-to-peer review with a BCBSMA medical director. This is a phone call where the prescriber explains the clinical reasoning directly. Citing the ADA Standards of Care recommendation for SGLT2 inhibitors in patients with ASCVD, HF, or CKD is effective here because BCBSMA's medical policies generally align with ADA guidelines [10].

Third, if the internal appeal is denied, patients can file an external appeal through the Massachusetts Office of Patient Protection. Massachusetts law provides a strong external review process, and the state's consumer protection framework for health insurance tends to favor coverage of guideline-recommended medications.

Some prescribers bypass the PA process entirely by prescribing a formulary-preferred SGLT2 inhibitor first. On certain BCBSMA plans, dapagliflozin (Farxiga) or canagliflozin (Invokana) may sit on a lower tier or have fewer restrictions. If the plan prefers a different SGLT2 inhibitor, switching is clinically reasonable since the class effect is well-established across the SGLT2 inhibitor trials. However, empagliflozin has the longest cardiovascular outcome data, and prescribers who prefer Jardiance specifically can use this as use in appeals.

BCBSMA Coverage for Jardiance's Expanded Indications

BCBSMA's coverage of Jardiance extends beyond type 2 diabetes, though coverage criteria differ by indication. Patients prescribed empagliflozin for heart failure or CKD face distinct prior authorization pathways.

For heart failure (both HFrEF and HFpEF), BCBSMA commercial plans generally cover Jardiance when prescribed by a cardiologist or when the prescriber documents NYHA Class II to IV symptoms and a prior trial of guideline-directed medical therapy (beta-blocker, ACE inhibitor/ARB/ARNI, and mineralocorticoid receptor antagonist). The 2022 AHA/ACC/HFSA heart failure guideline gives SGLT2 inhibitors a Class I recommendation for HFrEF, and this guideline endorsement makes PA approvals relatively straightforward [11].

For chronic kidney disease, coverage may require documentation that the patient has an eGFR between 20 and 45 mL/min/1.73 m² or an eGFR between 45 and 90 mL/min/1.73 m² with a urine albumin-to-creatinine ratio of 200 mg/g or greater. These criteria mirror the EMPA-KIDNEY enrollment parameters.

BCBSMA does not cover Jardiance for type 1 diabetes, weight loss, or other off-label uses. The FDA has not approved empagliflozin for these indications, and off-label PA requests are almost universally denied.

Jardiance vs. Other SGLT2 Inhibitors on BCBSMA Formularies

BCBSMA covers multiple SGLT2 inhibitors, and the relative formulary positioning of each one affects patient cost and access. Understanding the tier differences can save patients hundreds of dollars per year.

Dapagliflozin (Farxiga) often shares the same tier as empagliflozin on BCBSMA plans. Canagliflozin (Invokana) sometimes sits on a lower tier due to more aggressive manufacturer rebate negotiations, though its use has declined after post-marketing reports of increased amputation risk in the CANVAS trial, a finding not replicated with empagliflozin or dapagliflozin [12]. Ertugliflozin (Steglatro) was withdrawn by Merck in 2023 and is no longer available.

The combination product Synjardy (empagliflozin/metformin) may be covered on BCBSMA formularies but typically sits on a higher tier than taking the components separately. The same applies to Glyxambi (empagliflozin/linagliptin). Unless the convenience of a single pill meaningfully improves adherence, using individual generics for metformin alongside brand Jardiance is usually cheaper.

As of early 2026, no generic empagliflozin is available in the United States. Boehringer Ingelheim's patents on Jardiance extend into the late 2020s. When generic entry occurs, BCBSMA will likely move generic empagliflozin to Tier 1 or Tier 2 with no prior authorization required, similar to the trajectory of other diabetes drug classes after patent expiration.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, noted: "Access to SGLT2 inhibitors remains a challenge for many patients despite strong guideline recommendations. Insurance barriers, including prior authorization and step therapy, delay initiation of these evidence-based therapies by weeks or months."

Tips for Reducing Your Jardiance Costs on BCBSMA

Several strategies can lower out-of-pocket spending on Jardiance for BCBSMA members, beyond the manufacturer savings card.

Ask the prescriber to use the BCBSMA electronic prior authorization system, which processes requests faster than fax submissions. Faster PA means fewer gaps in therapy and fewer situations where a patient pays full price while waiting for approval.

If your plan requires a specialty pharmacy, confirm which pharmacy BCBSMA designates. Using an out-of-network pharmacy can double or triple the copay. BCBSMA's preferred specialty pharmacy network includes CVS Specialty and Accredo for most plans.

Consider a 90-day mail-order fill. BCBSMA offers mail-order pharmacy benefits through most plans, and the 90-day copay is typically 2 to 2.5 times the 30-day copay rather than 3 times. On a $75/month copay, switching to 90-day fills saves approximately $150 per year.

For patients who cannot afford the copay even with a savings card, Boehringer Ingelheim's patient assistance program provides Jardiance at no cost to uninsured or underinsured patients with household incomes below 400% of the federal poverty level. BCBSMA members with high-deductible plans who face financial hardship may qualify during the deductible phase of their plan year.

Patients enrolled in BCBSMA Medicare Advantage should verify whether their plan participates in the CMS-negotiated drug pricing provisions of the Inflation Reduction Act, which capped insulin copays at $35/month and set the $2,000 annual out-of-pocket maximum for Part D drugs starting in 2025 [13].